Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
While Google-backed personal genetics startup 23andMe is still working through its disagreements with the FDA, the company has impressed another part of the federal machine enough to win funding.
Your genetic data could be analyzed in another country, highlighting the need for an international, harmonized approach toward management of genomic data. An American company is already analyzing blood samples of Japanese women obtained from a prenatal test.
Personal genetics startup 23andMe is reportedly considering expanding overseas to so it can get sales back on track despite its standoff with the FDA.
California genetic testing startup Counsyl is launching BRCA and other predictive diagnostic tests. Crucially, $28 million in new Series D Financing will help kick all of this into high gear.
In the four months since 23andMe agreed to stop selling all health-related genetic tests in the U.S. while it submits them for a formal FDA review, the California company's future has become cloudier, not clearer. A recent blog post on its web site informed customers that executives continue to meet with regulators, but a resolution to the matter doesn't appear to be anywhere close to happening.
The controversial 23andMe Personal Genome Test has demonstrated some interesting ancestry numbers, according to a blogger at The Unz Review.
Two more customers are suing California maker of health-related genetic tests 23andMe for making bogus marketing claims. The lawsuits represent continued fallout over the FDA's assertion that the company marketed its products for years without proper regulatory approval.
The FDA backs a market that lets consumers easily gain information about their genomes and genetic risks, an agency official said, despite its move to stop 23andMe from selling its direct-to-consumer health-related genetic tests until they obtain formal regulatory approval.